alea-institute/kl3m-data-sample-004-shuffled huggingface dataset:
Editorial Note on Part 184
Editorial Note: Nomenclature changes to part 184 appear at 66 FR 56035, Nov. 6, 2001; 66 FR 66742, Dec. 27, 2001; 68 FR 15355, Mar. 31, 2003; 69 FR 13717, Mar. 24, 2004; 70 FR 40880, July 15, 2005; 70 FR 67651, Nov. 8, 2005; and 81 FR 49897, July 29, 2016.

§ 184.1272 L-Cysteine monohydrochloride. ( a ) L-Cysteine monohydrochloride is the chemical L-2-amino-3-mercaptopropanoic acid monohydrochloride monohydrate (C3H7O2NS HCl H2O).
( b ) The ingredient meets the specifications of the “Food Chemicals Codex,” 3d Ed. (1981), pp. 92-93, which is incorporated by reference. Copies may be obtained from the National Academy Press, 2101 Constitution Ave. NW., Washington, DC 20418, or may be examined at the National Archives and Records Administration (NARA). For information on the availability of this material at NARA, call 202-741-6030, or go to: *http://www.archives.gov/federal_register/code_of_federal_regulations/ibr_locations.html .*
( c ) The ingredient is used to supply up to 0.009 part of total L-cysteine per 100 parts of flour in dough as a dough strengthener as defined in § 170.3(o)(6) of this chapter in yeast-leavened baked goods and baking mixes as defined in § 170.3(n)(1) of this chapter.
( d ) This regulation is issued prior to a general evaluation of use of this ingredient in order to affirm as GRAS the specific use named.
[42 FR 14653, Mar. 15, 1977, as amended at 49 FR 5612, Feb. 14, 1984]
Missouri Court of Appeals

Southern District 

DECEMBER 28, 2015 

THE FOLLOWING CASES WERE AFFIRMED PURSUANT TO RULE 84.16(b). 

1. Case No. SD33784 

 Re: JAMES A. PERREN, 

 Plaintiff-Appellant, 

 v. 

 TIMOTHY A. PERREN and 

 DANIEL A. PERREN, 

 Defendants-Respondents.
§ 349.3 Definitions. As used in this part: ( a ) *Ophthalmic drug product.* A drug product, which should be sterile in accordance with § 200.50, to be applied to the eyelid or instilled in the eye.
( b ) *Astringent.* A locally acting pharmacologic agent which, by precipitating protein, helps to clear mucus from the outer surface of the eye.
( c ) *Buffering agent.* A substance which stabilizes the pH of solutions against changes produced by introduction of acids or bases from such sources as drugs, body fluids, tears, etc.
( d ) *Demulcent.* An agent, usually a water-soluble polymer, which is applied topically to the eye to protect and lubricate mucous membrane surfaces and relieve dryness and irritation.
( e ) *Emollient.* An agent, usually a fat or oil, which is applied locally to eyelids to protect or soften tissues and to prevent drying and cracking.
( f ) *Eyewash, eye lotion, irrigating solution.* A sterile aqueous solution intended for washing, bathing, or flushing the eye.
( g ) *Hypertonicity agent.* An agent which exerts an osmotic gradient greater than that present in body tissues and fluids, so that water is drawn from the body tissues and fluids across semipermeable membranes. Applied topically to the eye, a hypertonicity agent creates an osmotic gradient which draws water out of the cornea.
( h ) *Isotonicity.* A state or quality in which the osmotic pressure in two fluids is equal.
( i ) *Vasoconstrictor.* A pharmacologic agent which, when applied topically to the mucous membranes of the eye, causes transient constriction of conjunctival blood vessels.
§ 520.260 *n*-Butyl chloride. ( a ) *Specifications.* Each capsule contains 221, 442, 884, or 1,768 milligrams (mg); or 4.42 grams of *n*-butyl chloride.
( b ) *Sponsors.* See sponsors in § 510.600(c) of this chapter: ( 1 ) No. 023851 for capsules containing 221, 442, 884, or 1,768 mg, or 4.42 grams (g); and
( 2 ) No. 054771 for capsules containing 221 mg.
( c ) *Conditions of use in dogs* — ( 1 ) *Amount.* Administer capsules orally based on body weight as follows: ( i ) Capsules containing 221 mg: Under 5 pounds, 1 capsule per 11 ⁄ 4 pounds of body weight.
( ii ) Capsules containing 442 mg: Under 5 pounds, 1 capsule per 21 ⁄ 2 pounds of body weight.
( iii ) Capsules containing 884 mg: ( A ) Under 5 pounds, 1 capsule;
( B ) 5 to 10 pounds, 2 capsules;
( C ) 10 to 20 pounds, 3 capsules;
( D ) 20 to 40 pounds, 4 capsules;
( E ) Over 40 pounds, 5 capsules.
( iv ) Capsules containing 1,768 mg: Dogs weighing 5 to 10 pounds, 1 capsule.
( v ) Capsules containing 4.42 g: Dogs weighing 40 pounds or over, 1 capsule.
( 2 ) *Indications for use.* For the removal of ascarids (*Toxocara canis* and *Toxascaris leonina*) and hookworms (*Ancylostoma caninum, Ancylostoma braziliense,* and *Uncinaria stenocephala*) from dogs.
( 3 ) *Limitations.* Dogs should not be fed for 18 to 24 hours before being given the drug. Administration of the drug should be followed in 1 ⁄ 2 to 1 hour with a mild cathartic. Normal feeding may be resumed 4 to 8 hours after treatment. Animals subject to reinfection may be retreated in 2 weeks. A veterinarian should be consulted before using in severely debilitated dogs.
[86 FR 10819, Feb. 23, 2021]
**EXHIBIT 32.2****CERTIFICATION OF PRINCIPAL FINANCIAL OFFICER**     Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002     I, John P. Saldarelli, Treasurer and Chief Financial Officer(Principal Financial Officer) of American Property Investors,Inc., the General Partner of American Real Estate Partners, L.P.(the “Registrant”), certify that to the best of myknowledge, based upon a review of the American Real EstatePartners, L.P. quarterly report on Form 10-Q for the periodended September 30, 2005 of the Registrant (the“Report”):     (1) The Report fully complies with the requirements ofSection 13(a) or 15(d) of the Securities Exchange Act of1934, as amended; and     (2) The information contained in the Report fairlypresents, in all material respects, the financial condition andresults of operations of the Registrant. /s/    John    P. Saldarelli
§ 522.2444b Thiopental and pentobarbital powder for injection. ( a ) *Specifications.* Each gram of powder contains 750 milligrams (mg) of sodium thiopental and 250 mg of sodium pentobarbital powder for dilution with sterile water for injection.
( b ) *Sponsor.* See No. 061133 in § 510.600(c) of this chapter.
( c ) *Conditions of use* — ( 1 ) *Amount.* For total anesthesia, it is given at approximately 10 to 12 mg per pound of body weight over a period of 3.5 to 5 minutes. When preanesthetic medication is used, wait at least an hour before administering thiopental and sodium pentobarbital for injection, and the dosage necessary for anesthesia is reduced. Usually 1 ⁄ 2 to 2 ⁄ 3 the normal amount is adequate.
( 2 ) *Indications for use.* It is used as an anesthetic for intravenous administration to dogs and cats during short to moderately long surgical procedures.
( 3 ) *Limitations.* Federal law restricts this drug to use by or on the order of a licensed veterinarian.
[79 FR 16197, Mar. 25, 2014, as amended at 84 FR 8974, Mar. 13, 2019]
§ 706.2 Basis and scope. The specific policies contained in this part are worked out within the framework of DOE's general objectives for labor-management relations in the DOE program, namely: ( a ) Wholehearted acceptance by contractors and by labor and its representatives of the moral responsibility inherent in participation in the DOE program;
( b ) Development of procedures to assure ( 1 ) that all participants in the program are loyal to the United States including those whose participation involves the exercise of negotiating and disciplinary authority over bargaining units, and
( 2 ) that determination of unit, jurisdiction, and similar questions will not breach security;
( c ) Continuity of production at vital DOE installations;
( d ) Consistent with DOE's responsibility under the law, the least possible governmental interference with the efficient management expected from DOE contractors;
( e ) Minimum interference with the traditional rights and privileges of American labor.
#### § 225.202 Formula, production, and distribution records.

Records shall be maintained identifying the formulation, date of mixing, and if not for own use, date of shipment. The records shall be adequate to facilitate the recall of specific batches of medicated feed that have been distributed. Such records shall be retained on the premises for 1 year following the date of last distribution.

(Approved by the Office of Management and Budget under control number 0910-0152)

[51 FR 7390, Mar. 3, 1986]
§ 556.540 Progesterone. ( a ) [Reserved]
( b ) *Residues.* Residues of progesterone are not permitted in excess of the following increments above the concentrations of progesterone naturally present in untreated animals: ( 1 ) *Cattle and sheep.* ( i ) Muscle: 5 ppb.
( ii ) Liver: 15 ppb.
( iii ) Kidney: 30 ppb.
( iv ) Fat: 30 ppb.
( 2 ) [Reserved]
( c ) *Related conditions of use.* See §§ 522.1940 and 529.1940 of this chapter.
§ 203.38 Sample lot or control numbers; labeling of sample units. ( a ) *Lot or control number required on drug sample labeling and sample unit label.* The manufacturer or authorized distributor of record of a drug sample shall include on the label of the sample unit and on the outside container or packaging of the sample unit, if any, an identifying lot or control number that will permit the tracking of the distribution of each drug sample unit.
( b ) *Records containing lot or control numbers required for all drug samples distributed.* A manufacturer or authorized distributor of record shall maintain for all samples distributed records of drug sample distribution containing lot or control numbers that are sufficient to permit the tracking of sample units to the point of the licensed practitioner.
( c ) *Labels of sample units.* Each sample unit shall bear a label that clearly denotes its status as a drug sample, e.g., “sample,” “not for sale,” “professional courtesy package.” ( 1 ) A drug that is labeled as a drug sample is deemed to be a drug sample within the meaning of the act.
( 2 ) A drug product dosage unit that bears an imprint identifying the dosage form as a drug sample is deemed to be a drug sample within the meaning of the act.
( 3 ) Notwithstanding paragraphs (c)(1) and (c)(2) of this section, any article that is a drug sample as defined in section 503(c)(1) of the act and § 203.3(i) that fails to bear the label required in this paragraph (c) is a drug sample.
<TABLE> <S> <C>


<ARTICLE>                     5
<LEGEND>
This schedule contains summary financial information extracted from the Balance
Sheet and Statement of Operations as of and for the 39 weeks ended November 1,
1997 and is qualified in its entirety by reference to such financial statements
as included in the Company's Quarterly Report on Form 10-Q.
</LEGEND>
<CIK>                         0000813775
<NAME>                        Family Bargain Corporation
<MULTIPLIER>                                   1,000
       
<S>                                            <C>
<PERIOD-TYPE>                                  9-MOS
<FISCAL-YEAR-END>                              JAN-31-1998
<PERIOD-START>                                 FEB-2-1997
<PERIOD-END>                                   NOV-1-1997
<CASH>                                         3,319
<SECURITIES>                                   0
<RECEIVABLES>                                  0
<ALLOWANCES>                                   0
<INVENTORY>                                    43,413
<CURRENT-ASSETS>                               47,906
<PP&E>                                         21,390
<DEPRECIATION>                                 7,161
<TOTAL-ASSETS>                                 98,686
<CURRENT-LIABILITIES>                          38,775
<BONDS>                                        0
<PREFERRED-MANDATORY>                          0
<PREFERRED>                                    36
<COMMON>                                       49
<OTHER-SE>                                     14,201
<TOTAL-LIABILITY-AND-EQUITY>                   98,686
<SALES>                                        207,074
<TOTAL-REVENUES>                               207,074
<CGS>                                          134,105
<TOTAL-COSTS>                                  134,105
<OTHER-EXPENSES>                               79,929
<LOSS-PROVISION>                               0
<INTEREST-EXPENSE>                             3,964
<INCOME-PRETAX>                                (3,924)
<INCOME-TAX>                                   0
<INCOME-CONTINUING>                            (3,924)
<DISCONTINUED>                                 0
<EXTRAORDINARY>                                0
<CHANGES>                                      0
<NET-INCOME>                                   (3,924)
<EPS-PRIMARY>                                  (1.73)
<EPS-DILUTED>                                  (1.73)
        


</TABLE>
<PAGE>   1
                       [THE LOEWEN GROUP INC. LETTERHEAD]

(NYSE, TSE, ME: LWN)
        NEWS

Contact:
Thomas C. Franco
Broadgate Consultants, Inc.
Tel: (212) 232-2222

                              FOR IMMEDIATE RELEASE

                   LOEWEN GROUP ANNOUNCES FILING OF FORM 10-K
                       AND REDUCTION IN BOARD OF DIRECTORS

          -------------------------------------------------------------

VANCOUVER, BC, April 14, 1999 -- The Loewen Group Inc. (NYSE, TSE, ME: LWN)
today announced that it had filed its Form 10-K for the year ended December 31,
1998 with the Securities and Exchange Commission.

The Form 10-K included its audited financial statements.

In keeping with the previously announced plan to reduce the size of the Board to
seven members, the Board of Directors of The Loewen Group Inc. also announced
that Raymond Loewen will no longer be serving as a member of the Board and that
the director position previously occupied by Mr. Loewen has been eliminated. The
Board thanked Mr. Loewen for his service to the Company and, in particular, for
his vision and commitment as founder and longtime Chairman and Chief Executive
Officer.

The Loewen Group Inc. is one of the largest funeral home and cemetery operators
in North America. The Company employs approximately 16,000 people and owns or
operates more than 1,100 funeral homes and over 400 cemeteries across the United
States, Canada and the United Kingdom. Over 90 percent of the Company's revenue
is derived from the United States.

The Loewen Group's website is located at http://www.loewengroup.com

Note: Certain of the statements contained in the press release, including, but
not limited to, information regarding the future economic performance and
financial
<PAGE>   2
condition of the Company, the plans and objectives of the Company's management,
and the Company's assumptions regarding such performance and plans, are
forward-looking in nature. Additional information concerning important factors
that could cause actual results to differ from the forward-looking information
contained in this release is included in the Company's publicly filed quarterly
and annual reports.

                                      # # #
# United States Court **of Appeals**  **f or the Fifth Circuit** 

**____________** No. 22

- 10346 Summary Calendar

**____________ United States of America,**  Plaintiff

— Appellee **,**

versus **Fidel Ramos,** Defendant

— Appellant

**.**

**______________________________** Appeal from the United States District Court for the Northern District of Texas USDC No. 3:21

- CR

- 155

- 12

**______________________________** Before **Smith, Southwick,** and **Douglas,** Circuit Judges

**. Per Curiam**  **:** ***** The attorney appointed to represent Fidel Ramos has moved for leave to withdraw and has filed a brief in accordance with Anders v. California , 386 U.S. 738 (1967), and United States v. Flores , 632 F.3d 229 (5th Cir. 2011). Ramos has not filed a response. We have reviewed counsel’s brief and the rel evant portions of the record reflected therein. We concur with counsel’s assessment that the appeal presents no nonfrivolous issue for appellate

**_____________________**

* This opinion is not designated for publication. See **5th Cir . R.**  47.5. United States Court of Appeals Fifth Circuit 

### FILED January 11, 2023

Lyle W. Cayce Clerk Case: 22-10346 Document: 00516606723 Page: 1 Date Filed: 01/11/2023No. 22

- 10346

2 review. Accordingly, counsel’s motion for leave to withdraw is **GRANTED** , counsel is excused from further respo nsibilities herein, and the appeal is **DISMISSED**

. See **5th Cir. R.** 42.2

. Case: 22-10346 Document: 00516606723 Page: 2 Date Filed: 01/11/2023
#### § 290.5 Drugs; statement of required warning.

The label of any drug listed as a “controlled substance” in schedule II, III, or IV of the Federal Controlled Substances Act shall, when dispensed to or for a patient, contain the following warning: “Caution: Federal law prohibits the transfer of this drug to any person other than the patient for whom it was prescribed.” This statement is not required to appear on the label of a controlled substance dispensed for use in clinical investigations which are “blind.”
§ 522.1820 Pituitary luteinizing hormone powder for injection. ( a ) *Specifications.* The drug is a lyophilized pituitary extract. Each 6-milliliter vial contains an amount equivalent to 25 milligrams of standard pituitary luteinizing hormone and is reconstituted for use by addition of 5 milliliters of 0.9 percent aqueous sodium chloride solution.
( b ) *Sponsor.* No. 000061 in § 510.600(c) of this chapter.
( c ) *Conditions of use* — ( 1 ) *Amount.* Cattle and horses: 25 milligrams; swine: 5 milligrams; sheep: 2.5 milligrams; and dogs: 1.0 milligram. Preferably given by intravenous injection, it may be administered subcutaneously. Treatment may be repeated in 1 to 4 weeks, or as indicated.
( 2 ) *Indications for use.* As an aid in the treatment of breeding disorders related to pituitary hypofunction in cattle, horses, swine, sheep, and dogs.
( 3 ) *Limitations.* Federal law restricts this drug to use by or on the order of a licensed veterinarian.
[40 FR 13858, Mar. 27, 1975, as amended at 52 FR 7832, Mar. 13, 1987; 79 FR 16193, Mar. 25, 2014]
§ 346.18 Astringent active ingredients. The active ingredient of the product consists of any of the following when used within the concentration range established for each ingredient: ( a ) Calamine, within a concentration range of 5 to 25 percent by weight per dosage unit (based on the zinc oxide content of calamine).
( b ) Witch hazel, 10 to 50 percent.
( c ) Zinc oxide, within a concentration range of 5 to 25 percent by weight per dosage unit.
[55 FR 31779, Aug. 3, 1990, as amended at 59 FR 28767, June 3, 1994]
Figure 1 summarizes leak rates for commercial refrigeration equipment based on the SCAQMD 

data for 1722 pieces equipment in 2004 and 2005. 

Figure 1. Commercial Refrigeration Equipment

66.50%

10.00%

8.00%

15.50%

None

0 - 20%

20% - 35%

>35%

Figure 2 summarizes leak rates for comfort cooling equipment based on the SCAQMD data for 

2701 pieces equipment in 2004 and 2005.

Figure 2. Comfort Cooling Equipment

84.30%

2.70%

1.40%

11.60%

None

0 - 10%

10% - 15%

>15%
Figure 3 summarizes leak rates for industrial process refrigeration equipment based on the 

SCAQMD data for 349 pieces equipment in 2004 and 2005.

Figure 3. Industrial Process Refrigeration Equipment

69.40%

8.30%

4.80%

17.50%

None

0 - 20%

20% - 35%

>35%
Exhibit13.1

Certification Pursuant To Section 906 Of TheSarbanes-Oxley Act Of 2002

Pursuant to Section 906 of theSarbanes-Oxley Act of 2002 (subsections (a) and (b) of Section 1350,Chapter 63 of Title 18, United States Code), each of the undersignedofficers of Deutsche Telekom AG (the"Company"), does hereby certify, tosuch officer's knowledge, that:

The Annual Report on Form20-F for the year ended December 31, 2003 of the Company fully complieswith the requirements of Section 13(a) or 15(d) of the SecuritiesExchange Act of 1934 and information contained in the Form 20-F fairlypresents, in all material respects, the financial condition and resultsof operations of the Company.

|                     |  |                                                         |  |  |  |  |
|---------------------|--|---------------------------------------------------------|--|--|--|--|
| Dated:June 25, 2004 |  | /s/ Kai-UweRicke                                        |
|                |  | Name: Kai-Uwe RickeTitle: ChiefExecutiveOfficer         |
|                |  |
|                |  |
| Dated:June 25, 2004 |  | /s/ Dr.Karl-Gerhard Eick                                |
|                |  | Name: Dr. Karl-GerhardEickTitle: Chief FinancialOfficer |
|                     |

----
§ 516.135 Granting a request for determination of eligibility for indexing. ( a ) FDA will grant the request for determination of eligibility for indexing if none of the reasons described in § 516.133 for denying such a request applies.
( b ) When a request for determination of eligibility for indexing is granted, FDA will notify the requestor in accordance with § 516.137.
#### Reasor *v.*Reasor.

[No. 17,347.

Filed April 16, 1945.]

*Joseph E. Talbot,*of South Bend, for .appellant.

*Walter Rice, Arnold, Degnan, Goheen-& Zimmermam,*all of South Bend, for appellee.

Draper, C. J.

— The motion for new trial in this case was overruled on October 7, 1944. The assignment of errors and transcript of the record was filed on January 6, 1945. On February 6, 1945, the appellant’s briefs were filed. No extension of time for the filing of either was granted, nor was any petition for extension of time filed.

Under Rule 2-2 of the Supreme Court, 1943 Revision, the filing of the assignment of errors and transcript came too late. Under Rule 2-15 the filing of appellant’s briefs came too late.

Appellant seeks to meet the situation by a showing that the assignment of errors and transcript of the record was deposited in the mail, addressed to the Clerk of this court, postage prepaid, within the 90 day period, and the briefs were addressed to the Clerk of *536this court and registered with the express company within the 30 day period.

It is not enough that papers intended for filing be deposited in the mail or with the express company within the time limited for their filing. The rules require that they be deposited in the office of the Clerk of this court within the time limited. The appeal must, therefore, be dismissed.

Note. — Reported in 60 N. E. (2d) 536.